Compare Cytokinetics Inc (CYTK) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Sony Group Corp — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Sony Group Corp trades at $24.18 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 15.9× Cytokinetics Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Sony Group Corp for 96 Days on average.
| CYTK | SONY | |
|---|---|---|
Market Cap | $8.62B | $136.87B |
Volume | 2,594,626 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $87.26 | $30.26 |
52-Week Low | $54.76 | $19.32 |
Typical Hold Time | 19 Days | 96 Days |
Enterprise Value | $8.72B | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Sony (SONY) trades at $24.24, up 3.06% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with improved net income of $1.14T in 2025, though 2026 projections show a net loss. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and legal actions against AI copyright infringement.
Sony presents a mixed outlook with strong entertainment assets and improving cash flow offset by projected 2026 profitability challenges. The stock's current valuation metrics appear reasonable, but investors should monitor execution risks in content monetization and competitive pressures in the entertainment sector. The bullish analyst sentiment and technical momentum suggest near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
